<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284322</url>
  </required_header>
  <id_info>
    <org_study_id>H30142</org_study_id>
    <nct_id>NCT01284322</nct_id>
  </id_info>
  <brief_title>Fresolimumab In Systemic Sclerosis</brief_title>
  <official_title>OPEN LABEL TRIAL OF ANTI-TGF-BETA MAB, FRESOLIMUMAB, IN SYSTEMIC SCLEROSIS - A PHASE ONE BIOMARKER TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if fresolimumab is safe in treating people with
      systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of
      these individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety of fresolimumab in patients with scleroderma</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of fresolimumab on TGF-beta responsive gene expression in skin after treatment with fresolimumab compared to pre-treatment TGF-beta responsive gene expression.</measure>
    <time_frame>7 weeks</time_frame>
    <description>TGF-beta regulated skin gene expression</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Diffuse Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fresolimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fresolimumab</intervention_name>
    <description>intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients</description>
    <arm_group_label>Fresolimumab</arm_group_label>
    <other_name>GC1008</other_name>
    <other_name>anti-TGF-beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet ACR criteria for diffuse systemic sclerosis

          -  &lt; 24 months since onset of first SSc manifestation other than Raynaud's phenomenon

          -  Modified Rodnan Skin Score ≥ 15

          -  Male or female adult ( ≥ 18 years of age)

          -  Able and willing to give written informed consent and comply with study protocol

        Exclusion Criteria:

          -  Moderate or severe pulmonary disease w/ FVC &lt; 80% or DLCO &lt; 70% or ground glass and
             fibrosis &gt; 20% of lung fields by HRCT

          -  Treatment with investigational drug within 4 weeks of screening

          -  Ongoing use of high dose steroids (&gt; 10mg/day) or unstable steroid dose in past 4
             weeks

          -  Treatment with immunosuppressive, cytotoxic, or antifibrotic drug within 4 weeks of
             screening

          -  Positive for HIV, HBV, and/or HCV

          -  Known active infection (bacterial, viral, fungal, mycobacterial, or other); not
             including fungal infection of nail beds or any major infection requiring
             hospitalization or treatment with IV antibiotics within 4 weeks of screening

          -  Patients w/ history of malignancy or premalignant lesion

          -  History of keratoacanthoma or squamous cell carcinoma

          -  Moderate to severe hepatic impairment

          -  SSc renal crisis within 6 months or creatinine &gt; 2.0

          -  Lack of IV access for medication administration

          -  Moderate or severe cardiac disease with significant arrhythmia, heart failure, or
             unstable angina

          -  Anemia (Hb &lt; 8.5 gm/dL)

          -  Thrombocytopenia or blood clotting disorder

          -  Patients with organ transplant (including allogeneic bone marrow transplant)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lafyatis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University School of Medicine; Rheumatology/Arthritis Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>Robert Lafyatis</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

